Malignant Hyperthermia: The Ryanodine Receptor Runaway

What It Is and Why It Matters

Malignant hyperthermia is an autosomal dominant pharmacogenetic disorder of skeletal muscle in which exposure to specific anesthetic agents unmasks a latent defect in calcium regulation. Susceptible individuals are perfectly healthy in daily life — the phenotype is silent until a trigger is delivered under general anesthesia.

• Triggering agents: all volatile halogenated anesthetics (sevoflurane, desflurane, isoflurane, halothane) and the depolarizing neuromuscular blocker succinylcholine.
• Non-triggering (safe) agents: nitrous oxide, propofol, ketamine, etomidate, opioids, benzodiazepines, and all non-depolarizing relaxants (rocuronium, vecuronium).

Incidence of clinical events is roughly 1 in 10,000–100,000 anesthetics, more common in children and young men. It matters enormously because it is a true anesthetic emergency: without prompt recognition and dantrolene, a hypermetabolic spiral culminates in hyperthermia, hyperkalemic cardiac arrest, rhabdomyolysis, DIC, and death within an hour. Recognition converts a >70% historical mortality into <5%.

The Mechanism: A Ryanodine Receptor Runaway

Normal excitation–contraction coupling depends on the dihydropyridine receptor (DHPR / Ca_V1.1) in the T-tubule membrane sensing depolarization and mechanically opening the ryanodine receptor (RYR1), a calcium-release channel in the sarcoplasmic reticulum (SR). Calcium floods the cytosol, triggers actin–myosin contraction, and is then pumped back into the SR by SERCA — an ATP-consuming process.

In MH, gain-of-function mutations in RYR1 (chromosome 19q13, ~70% of cases) or, less often, CACNA1S (encoding DHPR) make the RYR1 channel hypersensitive. Volatile anesthetics and succinylcholine lower its activation threshold so it opens and stays open:

• SR calcium pours into the cytosol uncontrollably → sustained muscle contraction and rigidity.
• SERCA and other pumps run flat-out trying to clear the calcium → massive ATP and O₂ consumption, heat production, and CO₂ generation.
• ATP depletion and anaerobic metabolism cause lactic acidosis; the sarcolemma fails, releasing potassium, myoglobin, and creatine kinase (rhabdomyolysis).

The result is a self-amplifying hypermetabolic cascade — the 'runaway.'

Clinical Presentation and Classic Signs

The earliest and most sensitive sign is an unexplained rise in end-tidal CO₂ (EtCO₂) that does not respond to increased minute ventilation — reflecting the metabolic CO₂ surge. This typically precedes fever.

• Tachycardia and tachypnea (often the first vital-sign change), unexplained by anesthetic depth.
• Masseter muscle rigidity (MMR) after succinylcholine — trismus/'jaws of steel' — a classic early warning, sometimes a herald of full MH.
• Generalized muscle rigidity despite neuromuscular blockade.
• Hyperthermia, often a late sign, but temperature can rise ~1–2 °C every 5 minutes, exceeding 40–43 °C.
• Mixed respiratory and metabolic acidosis, hyperkalemia, and dark 'cola-colored' urine (myoglobinuria).

Hemodynamic instability, ventricular arrhythmias (from hyperkalemia), mottled/cyanotic skin, and profuse sweating follow. The combination of soaring EtCO₂, tachycardia, and rigidity during a volatile/succinylcholine anesthetic should trigger the MH pathway until proven otherwise.

Diagnosis: From the Bedside Score to the Contracture Test

Intra-operative diagnosis is clinical and urgent — you treat first and confirm later. The Clinical Grading Scale (Larach) assigns points across six domains (rigidity, muscle breakdown, respiratory acidosis, temperature increase, cardiac involvement, family history) to rate the likelihood of MH.

• Arterial blood gas: combined respiratory and metabolic acidosis; PaCO₂ often >60 mmHg with a base deficit.
• Rising EtCO₂ refractory to hyperventilation; falling SpO₂.
• Hyperkalemia, and markedly elevated creatine kinase (can exceed 10,000–100,000 IU/L) with myoglobinuria.

The confirmatory gold standard is the caffeine-halothane contracture test (CHCT) in North America / in-vitro contracture test (IVCT) in Europe: a fresh muscle biopsy is exposed to halothane and caffeine, and an abnormally strong contracture confirms susceptibility. It has ~97–99% sensitivity but lower specificity, requires a viable biopsy at a specialized center, and cannot be shipped. Genetic testing for RYR1/CACNA1S variants is highly specific but detects susceptibility in only ~50–70% of families, so a negative gene test does not exclude MH.

Management at the Mechanism Level

Treatment attacks each rung of the cascade. Call for help and the MH cart immediately.

• Stop all triggers — discontinue volatile agents and succinylcholine; switch to a non-triggering (propofol/TIVA) technique. Do not waste time changing the anesthesia machine before dantrolene.
• Dantrolene is the specific antidote: it inhibits RYR1 calcium release, halting the calcium leak at its source. Give 2.5 mg/kg IV bolus, repeating every 5–10 minutes (up to ~10 mg/kg or more) until EtCO₂, rigidity, and temperature fall. The newer formulation, Ryanodex, reconstitutes far faster than older dantrolene.
• Hyperventilate with 100% O₂ at high flows to wash out CO₂ and the volatile agent.
• Active cooling (cold IV saline, surface cooling, lavage) until temperature <38 °C.
• Treat hyperkalemia (calcium, insulin/glucose, bicarbonate) — the leading cause of arrhythmic arrest; correct acidosis; maintain urine output with fluids ± bicarbonate/diuretics to protect kidneys from myoglobin.

Continue dantrolene and monitor in ICU for at least 24–48 h — recrudescence occurs in up to 20–25% of cases.

Mimics, Pitfalls, and Significance

The MH label is over-attributed, so distinguishing it from mimics is crucial:

• Neuroleptic malignant syndrome (dopamine antagonists; days-long onset) and serotonin syndrome (serotonergic drugs; clonus and hyperreflexia) both cause hyperthermia and rigidity but are not triggered by anesthetics — see the comparison table.
• Thyroid storm, pheochromocytoma, sepsis, iatrogenic overheating, and inadequate anesthesia can raise EtCO₂ and temperature.
• Associated myopathies: RYR1 mutations also cause central core disease and multiminicore disease; these patients are MH-susceptible. King–Denborough syndrome and, historically, some links to exertional heat illness/rhabdomyolysis are recognized.

Pitfalls: isolated masseter rigidity after succinylcholine may not progress to full MH but warrants heightened vigilance; a normal genetic test does not clear a patient; and dantrolene must be reconstituted early — delay costs lives. Any patient or first-degree relative with a suspected event should be referred for CHCT/IVCT and counseled to carry an MH-alert card and inform every future anesthetist.

Malignant hyperthermia vs. its key clinical mimics

Feature	Malignant Hyperthermia	Neuroleptic Malignant Syndrome	Serotonin Syndrome
Trigger	Volatile anesthetics, succinylcholine	Dopamine antagonists (antipsychotics), abrupt L-dopa withdrawal	Serotonergic drugs (SSRIs, MAOIs, tramadol, linezolid)
Onset	Minutes to hours (intra-op)	Days to weeks	Hours (<24 h)
Neuromuscular sign	Generalized/masseter rigidity, no reflex change	Lead-pipe rigidity, bradyreflexia	Clonus, hyperreflexia (legs > arms)
Core defect	RYR1 skeletal-muscle Ca2+ channel	Central dopamine D2 blockade	Excess CNS serotonin (5-HT2A)
Specific antidote	Dantrolene	Dantrolene/bromocriptine (supportive)	Cyproheptadine (supportive)
Onset of rigidity vs. fever	Metabolic signs (EtCO2) often precede fever	Rigidity precedes fever	Agitation/clonus precede fever